

www.tajpharma.com

\*For gastro-oesophageal reflux disease

- GERD.
- Heart Burn & Hyperacidity.
- Reflux Oesophagitis.
- Regurgitation & Flatulence.
- Gastric & Paptic Ulcer

**ACIEZYME<sup>®</sup>-D**  
(Rabeprazole & Domperidone) **SR**  
Sustained Release Capsules



**20+30 MG**  
**ACIEZYME<sup>®</sup>-D**  
(Rabeprazole & Domperidone) **SR**  
Sustained Release Capsules

ACIEZYME<sup>®</sup> -D SR (Rabeprazole 20mg with Domperidone 30mg) Acid is secreted in the stomach by a type of cell called the parietal cell. There is an enzyme pump (called the H<sup>+</sup>/K<sup>+</sup> ATPase pump) on the side of this cell closest to the stomach lining that pumps acid into the stomach. This is known as the proton pump. The class of drugs to which rabeprazole belongs inhibits this pump. This is why they're called proton-pump inhibitors. Specifically, rabeprazole blocks the final step in the acid secretion. In contrast to the other PPIs, rabeprazole forms a partially reversible bond with the proton pump. It also works at a broader range of stomach pH. For these reasons, it may work for longer than other PPIs. Domperidone is a derivative of benzimidazole that possesses both prokinetic and antiemetic properties due to its inhibitory action at dopamine D2 receptors.

ACIEZYME<sup>®</sup> -D SR Rabeprazole is an antiulcer drug in the class of proton pump inhibitors (PPI)

ACIEZYME<sup>®</sup> -D SR Rabeprazole is a PPI that suppresses gastric acid secretion by inhibiting the gastric H<sup>+</sup>/K<sup>+</sup> ATPase at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, rabeprazole has been characterized as a gastric proton pump inhibitor. Rabeprazole blocks the final step of gastric acid secretion. Onset of action is 1 hour. Duration 24 hours. Absorption Oral bioavailability is about 52% and peak plasma concentrations are reached about 3.5 hr after oral admin. The median inhibitory effect of rabeprazole on 24 hour gastric acidity is 88% of maximal after the first dose.

ACIEZYME<sup>®</sup> -D SR Domperidone is a dopamine antagonist with anti-emetic properties domperidone does not readily cross the blood-brain barrier. Its anti-emetic effect may be due to a combination of peripheral (gastrokinetic) effects and antagonism of dopamine receptors in the chemoreceptor trigger zone, which lies outside the blood-brain barrier in the area postrema. Studies in man have shown oral domperidone to increase lower esophageal pressure, improve antroduodenal motility and accelerate gastric emptying. There is no effect on gastric secretion. In fasting subjects, domperidone is rapidly absorbed after oral administration, with peak plasma concentrations at 30 to 60 minutes. The low absolute bioavailability of oral domperidone (approximately 15%) is due to an extensive first-pass metabolism in the gut wall and liver. Although domperidone's bioavailability is enhanced in normal subjects when taken after a meal, patients with gastro-intestinal complaints should take domperidone 15-30 minutes before a meal. Reduced gastric acidity impairs the absorption of domperidone.

FORMULATIONS AVAILABLE: CAPSULE ACIEZYME<sup>®</sup> -D SR

Each Hard Gelatin Capsule contains:

Rabeprazole Sodium IP (as enteric coated) 20 mg

Domperidone Maleate IP (= to Domperidone) (10 mg as IR, 20 mg as SR) 30 mg

DOSAGE AND ADMINISTRATION: One capsule once daily.

INDICATIONS:

ACIEZYME<sup>®</sup> -D SR is indicated for the relief of symptoms of

- Dyspepsia
- GERD
- Nausea associated with acid peptic disorders
- Post-operative nausea and vomiting
- Chronic gastritis

**Food and Drug Administration (FDA) approved .Prescription Only (POM)**

A Taj Pharma India Product